Enantioseparation of Amino Acids Using a Chiral Recognition Polymer
Researchers at UCLA have developed a new chiral recognition polymer that has the following advantages: 1. Direct separation of free amino acids. 2. Usable for both analytical and preparative purposes. 3. Uses aqueous solutions and alcohol; no buffer solutions are needed. 4. Easy scale-up. 5. A large chiral recognition capacity compared to natural biopolymers, such as Human Serum Albumin (HSA) and Bovine Serum Albumin (BSA). 6. Reusable. 7. Can be used as a chiral sensor. 8. Potential for adaptation for pharmaceutical separations.This new polymer strongly interacts with one enantiomeric form of an amino acid or component in a racemic mixture enabling chiral separations. An efficient way of employing the polymer to separate enantiomers of amino acids is by the use of a column containing a high-surface-area of the polymer. Experimental data has shown a separation factor of alpha = 8.4 for dl-phenylalanine using a 250mm column. Since alpha > 2 is considered to be potentially useful commercially, alpha of 8.4 is remarkable.
Patent Number: US6265615B1
Application Number: US1999322327A
Inventor: Kaner, Richard B. | Knobler, Charles M. | Guo, Hailan
Priority Date: 1 Jul 1998
Priority Number: US6265615B1
Application Date: 28 May 1999
Publication Date: 24 Jul 2001
IPC Current: C07B005700 | C08G007302
US Class: 564424 | 210649 | 210661
Assignee Applicant: The Regents of the University of California
Title: Chiral recognition polymer and its use to separate enantiomers
Usefulness: Chiral recognition polymer and its use to separate enantiomers
Summary: The PM is useful for separation of racemic mixtures of compounds such as drugs or amino acids.
Novelty: Chiral recognition polymers, especially chiral polyaniline, useful for selective and reversible retention of enantiomers in a racemic mixture are prepared by doping the polymer
化工/材料
化工/材料应用
6265615
Background Enantioseparations are becoming increasingly important because the U.S. Food and Drug Administration has declared if a drug is chiral, the biological effects of both enantiomers must be determined. Many procedures for resolutions of D, L-amino acids have been documented on an analytical scale. The limitations of these methods is generally the economic cost, in addition to the difficulty of being scaled up. Additional Technologies by these Inventors Tech ID/UC Case 20086/1998-601-0 Related Cases 1998-601-0
美国
